Floatz logo

Entospletinib

Nucleophosmin 1-mutated Acute Myeloid Leukemia

Kronos BioSmall moleculePhase 3Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Nucleophosmin 1-mutated Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Shen yang
Phase 3B
Azacitidine
Shen yang
Phase 2B
Venetoclax
Kura Oncology, Inc.
Phase 2B
Daunorubicin
Shen yang
Phase 2B
Arsenic Trioxide
The University of Hong Kong
Phase 2CCC

View all 14 →

Same molecule, other indications

Entospletinib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →